Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000819263 | SCV000959913 | uncertain significance | Naxos disease; Arrhythmogenic right ventricular dysplasia 12 | 2025-01-27 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 146 of the JUP protein (p.Glu146Lys). This variant is present in population databases (rs146581757, gnomAD 0.007%). This missense change has been observed in individual(s) with left ventricular noncompaction (PMID: 28855170). ClinVar contains an entry for this variant (Variation ID: 661772). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001759599 | SCV001985158 | uncertain significance | not provided | 2020-03-20 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Reported in ClinVar as a variant of uncertain significance (ClinVar Variant ID# 661772; Landrum et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29606362, 28855170, 32600061) |
Ambry Genetics | RCV002332696 | SCV002632972 | uncertain significance | Cardiovascular phenotype | 2025-02-10 | criteria provided, single submitter | clinical testing | The p.E146K variant (also known as c.436G>A), located in coding exon 2 of the JUP gene, results from a G to A substitution at nucleotide position 436. The glutamic acid at codon 146 is replaced by lysine, an amino acid with similar properties. This alteration has been reported in a left ventricular non-compaction cohort and an arrhythmogenic right ventricular cardiomyopathy (ARVC) cohort (Wang C et al. J Am Heart Assoc, 2017 Aug;6; Ruiz Salas A et al. Rev Esp Cardiol (Engl Ed), 2018 Dec;71:1018-1026). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Fulgent Genetics, |
RCV000819263 | SCV002784969 | uncertain significance | Naxos disease; Arrhythmogenic right ventricular dysplasia 12 | 2021-11-12 | criteria provided, single submitter | clinical testing |